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has shown that as the molar ratio of 1 is reached, bilirubin solubility comes into question. There is a lot of controversy about how soluble bilirubin really is even with albumin present. I don't think we appreciate the fact that bilirubin may come out of solution a lot sooner than we think it does or it co-crystallizes.
DR. EBBESEN: It may be appropriate to assess the amount of free bilirubin by measuring the cutaneous bilirubin. Based on my earlier work, 2 -4 I think that everything that decreases the binding from bilirubin to albumin increases the cutaneous bilirubin. In the most recent group of infants I have studied, sick infants have a higher cutaneous bilirubin than do normal infants -about 10 mol/l. DR. AHLFORS: It would be interesting to see what the transcutaneous data show and whether we can develop indexes based on the cutaneous levels.
DR. DENNERY: Dr. Hansen, have you looked at the effect of bilirubin on mitogen-activated protein kinases or other kinases. Some of the kinases produce positive reactions and others produce negative reactions; if bilirubin were to inhibit all kinases, including some that are involved in oxidative signaling and damage, it may be one mechanism by which it could be protective in some instances against oxidative injury.
DR. HANSEN:
We have looked at a fair number of protein kinase interactions. We have just finished a study in which we looked at casein kinase, which has a different substrate charge than the other kinases. The effect doesn't appear to be substratecharge dependent. We have had an opportunity to look at those other kinases, and we hope to publish our results in the near future.
DR. BHUTANI: Is it difficult to work with a neonatal animal model? Seven days in some of these animals is probably more like 4 or 8 weeks of human age. In the first week, most human newborns experience hyperventilation and respiratory alkalosis while their bilirubin level is rising. Does the expression of phosphoglycoprotein (PGP) or the albumin binding have an impact on any of these data when you are studying these animals? DR. HANSEN: Probably not, because these are homogenized brains that were removed from the decapitated animal so that whatever the effect of PGP may be in this context is essentially unknown. However, we have extracted the mitochondria directly from the brain and then sonicated that to rupture the mitochondria and use the mitochondrial membranes directly. I am hesitant to think that either albumin binding or phosphoglycoprotein plays any role in that particular set of data.
DR. McDONAGH: It's unfortunate that Brodersen's original article has been cited so often as being definitive evidence for an oxidant in brain. It was a very preliminary communication, and the evidence is very shallow. In your studies, you mentioned disappearance of bilirubin based on loss of absorbance. Are you sure that bilirubin is being oxidized? What evidence is there for that? There could be other factors that lead to loss of absorption.
DR. HANSEN: It's the crucial question. I cannot be absolutely sure except to say that the products are colorless, which indirectly suggests that they are those small molecules that Dr. Lightner DR. CASHORE: Several factors converged to cast doubt on the clinical validity of the binding methodology we were using. First, we adopted as informal criteria for exchange transfusion the intervention criteria of the phototherapy study, and this in various forms was initially adopted as an algorithm for exchange transfusion. At the time we did large numbers of exchange transfusions on infants based on birth weight, and people pretty much stuck with that approach until they determined that low bilirubin kernicterus was resolving and that phototherapy appeared to be safe and effective in that same population of infants. Also extending that algorithm to infants with lower and lower birth weights created more exchange transfusions at lower bilirubin levels with no apparent effect.
Second, several different methodologies for estimating free bilirubin and bilirubin binding were introduced at about the same time in the early 1980s. A number of us sat through an entire day of Food and Drug Administration (FDA) hearings on these methodologies. The FDA refused to approve them as clinical tests because they said there was no way to relate them to an endpoint that was so rare. That being the case, it became hard to establish these as methodologies on which people could rely clinically. Since that time, we have learned a great deal more about the neurochemistry and neurophysiology of bilirubin toxicity. Although we were using different methods, in many cases the information was analogous across several different methodologies. Although low-bilirubin kernicterus disappeared initially, we were not aware that kernicterus might reemerge, resulting in an increasing need for exchange transfusion in early discharged infants. The lack of our ability to correlate the binding measurements with endpoints in that setting led us to abandon them altogether.
DR. YEUNG: The albumin binding or cord blood binding capacity study 5 is a much more useful test clinically. The reason is simple, especially for our community in this Southeast Asian area where consumption of herbs was so prevalent. Many herbs could actually move the bilirubin away from protein binding. It is not possible to predict the severity of the problem by relying solely on the absolute bilirubin level. Some of the presentation by previous speakers indicate that the range of identifiable so-called free bilirubin, even at a certain narrow point of total bilirubin level, was so wide. It's rather difficult to use a total bilirubin level alone and predict how much unbound bilirubin is present. Once so much unbound bilirubin is generated because of an insufficient amount of available protein, most of the unbound bilirubin would be attached to cell surface anyway. How can you assess in a serum and use that number to infer how much unbound bilirubin had been generated? That's why I never use unbound bilirubin alone as a guide in making clinical decisions.
DR. STEVENSON: Dr. Ahlfors, I wonder whether our approaches are appropriate for assessing risk; we know that we are dealing with a very dynamic and probably unstable state. In our studies 6 of children with hemolytic disease, for example, the rates at which they hemolyze vary dramatically over time. Bilirubin might move out of circulation variably depending on the factors you discussed. Do any of the models take into consideration nonsteady state? The other factor that should be considered is duration of exposure.
DR. AHLFORS: I agree. We need to approach treatment of these infants as evolving in two areas. One is preventing infants from reaching the point where you need to assess the need to do more than phototherapy. When infants do have unexpected high bilirubin levels and treatment becomes necessary, then time of exposure must be considered. The other area is to determine what parameters can be assessed that will help in making a treatment decision. We have had approximately five infants return with bilirubin levels over 30 mg/dl with no obvious cause. A decision must be based not only on medical judgment but also on other factors such as legal issues. Measuring only total bilirubin levels doesn't provide the whole picture. If you can measure free bilirubin, that information provides a clearer picture. If you can assess the child with an Algo Hearing Screen that helps you make a decision. All of these assessments should be weighed when determining management. My overall approach is to base treatment on as much information as I can gather. The models help us determine what the important circumstances are. You are never in a steady state. We need to stop thinking of bilirubin as being just in the vascular space. Bilirubin in the blood never causes toxicity; its bilirubin that's not in the blood that causes toxicity. We are using the blood level to determine toxicity that exists outside the blood, which is an inaccurate measurement. You can't assess the size of the ''iceberg'' by looking at the tip.
DR. FANAROFF: We need to appreciate that kernicterus is a spectrum of disorders. There is a huge range, starting from something very mild and extending to something very severe. We have also focused a lot of the attention on the full-term and nearterm infant, but many of the problems may relate to the extremely low-birth-weight infant. Is there a threshold level, or should I worry every time that bilirubin reaches 10 or 12 mg in infants with birth weights <1500 g? Should I measure free bilirubin? Should I measure the auditory-evoked responses? Both? Neither? DR. CASHORE: The sets of numbers posted on nursery walls are simply not based on an endpoint that would allow validation. It seems intuitively correct that if the blood-brain barrier is less mature, the infant is at higher risk of comorbidities, and the plasma If we look in neonatal follow-up clinics, we have trouble identifying neurologic morbidities that we can clearly identify with bilirubin-related brain injuries. We rarely find classic kernicterus. Even when low-bilirubin kernicterus was present at autoposy examinations, the preterm survivors didn't have anything corresponding to low-bilirubin kernicterus in the follow-up clinic. We may also need to look at this spectrum of disorders from the standpoint of the maturation of the systems involved. For example, the adult or young adult patient who develops bilirubin-related brain damage with Crigler-Najjar syndrome later on doesn't always have the classic findings that we see in infants, and the abnormalities may also have a pattern of waxing and waning. It could be that the target areas of the brain are different at different developmental ages according to the state of both myelination and function. Perhaps some of what we see in some of the small premature infants could be related to their mild to moderate levels of bilirubin even though treated. At present time, we don't have a physiologic, pathophysiologic, or neurologic endpoint to validate that possibility. As we looked at the studies of low-bilirubin kernicterus, it wasn't common, and the plasma bilirubin levels at which this was found varied enormously. Even if someone followed binding capacity, free bilirubin levels, and other variables, some of the patients who came to autopsy with low-bilirubin kernicterus had undergone multiple exchange transfusions at what were then considered the correct levels.
In summary, we have little scientific validation for the practice of adapting certain numbers at certain birth weights or certain gestational ages to treat infants in specific ways. If we attempt to refine the analysis, we had better find a good way to validate some assessment of neurophysiologic function in newborn infants who are not yet mature and some way of reliably measuring something called ''free bilirubin'' in plasma samples. We need to ensure that what we are measuring is giving us additional important information, not just adding another number to another table whose relevancy to treatment and outcome is already questionable.
DR. SHAPIRO: I don't think it's possible to predict outcome in these infants when they leave the hospital or even at 1 or 2 years of age. It takes 5 or 7 years to know if treatment was correct, and then only if you ask the right questions. Studies by O'Dell in 1970 8 and Johnson and Boggs in 1974 9 looked at the duration of hyperbilirubinemia over a certain level. Other retrospective studies 10 have looked at deafness, and a few studies have noted the importance of duration. Today we can look at different outcome measures with magnetic resonance imaging, which may be available soon after nursery, auditory brainstem responses (ABRs) in the nursery, and perhaps more sophisticated electrophysiologic testing later. Even if the ABRs are abnormal, that doesn't mean the children are abnormal. We've seen children who looked totally normal at 1 or 2 years of age, who, by the age of 5 or 7 years, had auditory processing problems. I think we need to compare those outcomes in prospective studies with newborn data. I'm not sure I can answer your questions as to what the guidelines are for the general audience. Looking at a hearing screen is valid if the screen is abnormal. But many subtle abnormalities go undetected with a hearing screen. Dr. Johnson's BIND scale, which is a composite of all clinical examinationsposture, tone, and so forth -may be important.
DR. AHLFORS: We don't have population reference values. For example, there has never been a systematic investigation of infants with birth weights of 500 g to calculate their unbound bilirubin on day 1, 2, 3, etc. We need this information to assess a particular infant's status in relation to the population as a whole. This may not tell you exactly at what level you should intervene at, but at least you would know where that infant fits relative to the population. We've had to rely on data from separate small studies, and that approach hasn't been adequate. We need to take a much broader look. It doesn't take long to collect that kind of data because the bilirubin information is collected every day in this population.
DR. XIAO MING BEN:
We have the impression that the auditory system has something to do with unbound bilirubin, but the relation is not clear. We know that unbound bilirubin and free bilirubin have at least a theoretical variance. The level of bilirubin that we get from animal and human blood samples differs in the unbound bilirubin we detect. How can you guarantee that the value of unbound bilirubin is correct?
DR. AHLFORS: When we say we have been measuring levels for years, we should really say that we have been measuring ''something.'' One of the difficulties of doing binding is that there has always been only one way to measure free bilirubin. We are investigating microcalorimetry and other procedures to try to find other reliable ways to measure binding without perturbing the system greatly. The most important concern, rather than thinking that we are measuring exactly what we think we are, is that we do it the same way all the time. So many different kinds of binding tests have evolved, and it's hard to compare their results because most of them are aimed at measuring binding capacity or saturation of albumin, which is difficult to compare with free bilirubin. As a consequence, whatever we measure, when compared with ABR or for kernicterus, for example, looks better than the total bilirubin. However, free bilirubin includes the total bilirubin. Total bilirubin and free bilirubin should not be perceived as two different measurements. Free bilirubin is a function of the total bilirubin, and when you measure it, you are reflecting the albumin and binding constant in one number.
DR. YEUNG: In the first method we proposed, we saw that in an electrophoretic pattern, we can estimate the proportion of unbound bilirubin that is free bilirubin. So to say we are able to see free bilirubin is untrue because it depends on the method being used. With our method, we actually see the unbound bilirubin when we oversaturate the sample of serum or the sample of albumin solution with bilirubin. Then we look at the electrophoretic pattern, and we can see the free bilirubin. By adding herbs or other substances that compete for the protein binding, we are able to see an increase of unbound bilirubin. As with protein electrophoresis, you can actually calculate how many albumin sites are occupied, how much 1, how much 2. That's why we can progressively pattern the saturation point for bilirubin.
DR. SHAPIRO: The important factor is the brain -or rather parts of the brain -not the free bilirubin. The auditory system is important because it is affected. Other parts of the brain are affected and are no less important, but we have a test for the auditory system. We can't yet measure the cerebellum or the basalganglia in the newborn. We need to develop a formula that can assess how much bilirubin is getting into the brain.
DR. HANSEN: One difficulty we all face is identifying the vulnerable individual. Dr. Johnson raised a poignant question in the title of her recent article, ''When To Treat and When To Worry.'' We don't yet have the tools to answer this question. Which infant in a thousand will not tolerate a bilirubin level of 400 to 600 mol/l? What is the difference between the infant with that level who cannot tolerate it and the infant who survives apparently without harm? Maybe we could begin to answer this question by collecting data on both groups: those that are kernicteric and those with extreme levels who survive without damage. As a starting point, we could compare the case histories and laboratory findings to see if we can detect a pattern. We may not be ready to do a controlled trial, but this would be a reasonable and achievable beginning.
